DHR Research Update — September 23, 2026
Updated Thesis
Danaher is a diversified life-sciences and diagnostics platform spanning three segments: Life Sciences (mass spectrometers, flow cytometry, genomics, bioprocess technologies), Diagnostics (chemistry, immunoassay, microbiology, hematology, molecular and pathology systems), and Environmental & Applied Solutions (water quality and product-identification instrumentation). The business quality is high, anchored in intangible assets and switching costs: instruments are embedded in regulated laboratory workflows, and the consumables, reagents and service annuity that follows an installed base produces TTM gross margin of 58.5% and TTM operating margin of 20.4%. Growth has re-accelerated modestly, with revenue up 5.5% and earnings up 56.8% in the most recent quarter, while TTM net margin of 15.9% and ROE of 7.7% show the earnings base is still recovering rather than fully normalized.
The investment grade as of this refresh is B — solid business quality. A-tier business, B-tier valuation with 29.6% upside to $286.52 blended fair value.
Grade Change
In this research cycle, the investment grade for Danaher Corporation moved from A- to B. A-tier business, B-tier valuation with 29.6% upside to $286.52 blended fair value.
Key Metrics at a Glance
- Revenue growth: +5.5% year over year
- Net margin: 15.9%
- Fair value upside: +29.6% to our estimate of $287
Current price: $221.12
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Danaher Corporation remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full DHR research →](/stocks/DHR)